GoldenGolden
Editas Medicine

Editas Medicine

Editas Medicine is a genome editing company founded in 2013 that is using CRISPR technology to treat patients with genetically defined diseases.

Editas Medicine is a biotechnology and synthetic biology company using genetic engineering to create therapeutics for treating disease. It is headquartered in Cambridge, Massachusetts, and was founded in 2013 by Feng Zhang, J. Keith Joung, and Jennifer A. Doudna.

Editas Medicine has developed a proprietary genome editing platform based on CRISPR using different engineered variants of CRISPR effector nucleases Cas9 and Cpf1 (also known as Cas12a). The company is working on gene editing efficiency and delivery of treatment to the sight of disease. Editas Medicine is in the discovery stage of developing CRISPR gene edit treatments for the following conditions:

Leber Congenital Amaurosis 10

Usher Syndrome 2a

HSV-1

T Cells for cancer treatments

Beta Thalassemia

Sickle Cell

Cystic Fibrosis

Alpha-I Antitrypsin Deficiency

Editas Medicine was previously founded under the name Gengine by Feng Zhang, George Church, Keith Joung, David Liu all from The Broad Institute at MIT and Harvard along with Jennifer Doudna from the University of California, Berkeley. Jennifer Doudna left and co-founded Intellia Therapeutics.

Timeline

November 2013
Editas Medicine raises a $43,000,000 series A round from Flagship Pioneering, Partners Innovation Fund, Polaris Partners and Third Rock Ventures.
2013
Editas Medicine was founded by Feng Zhang, J. Keith Joung and Jennifer Doudna.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Editas Medicine Series A round November 2013
43,000,000
November 2013
1 Result
Results per page:
Page 1 of 1

SBA Awards

SBA Award
Agency
Award Type
Amount (USD)
Date Awarded
Editas Medicine SBIR Phase I Award, July 2015
SBIR
225,000
July 2, 2015
1 Result
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Andrew Hack, M.D., Ph.D.

CFO

Charlene Stern, J.D., Ph.D.

Vice President and Head of Legal

Charles Albright, Ph.D.

CSO

Katrine Bosley

CEO

Semi Trotto

Vice President and Head of Human Resources

Timothy D. Hunt, J.D.

Senior Vice President of Corporate Affairs

Vic Myer, Ph.D.

Chief Technology Officer

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Ben Adams
February 8, 2021
FierceBiotech
Cynthia Collins is out as Editas Medicine's CEO as chairman James Mullen takes over from Feb. 15 after the biotech lost its Allergan/AbbVie partnership on its leading eye disease drug EDIT-101.
Andrew Dunn and Allison DeAngelis
January 15, 2021
Business Insider
Gene therapy biotechs were overshadowed and struggled, while a highly debated theory on treating Alzheimer's disease got a boost.
BioSpace
November 9, 2020
BioSpace
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Lisa A. Michaels, M.D., as the Company's Executive Vice President and Chief Medical Officer, effective immediately.
Alex Keown
June 5, 2020
BioSpace
Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers.
June 1, 2020
BioSpace
ImmunoGen Appoints Stacy Coen as Senior Vice President and Chief Business Officer - read this article along with other careers information, tips and advice on BioSpace
BioSpace
May 15, 2020
BioSpace
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced results from a pre-clinical study evaluating multi-gene knockout and transgene knock-in using its proprietary engineered CRISPR-Cas12a (EngCas12a) in induced pluripotent stem cells (iPSCs) for the development of engineered cell immunotherapy medicines.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.